End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study
Publication: Journal of Comparative Effectiveness Research
Abstract
Objective: The aim of the present study was to estimate the cost of treating patients with lung cancer at their end-of-life (EOL) phase of care in Greece. Materials & methods: A hospital-based retrospective study was conducted in the Oncology Unit of ‘Sotiria’ Hospital, in Athens, Greece. All lung cancer patients who died between 1 January 2015 and 31 December 2018 with at least 6 months follow-up were enrolled in the study. Healthcare resource utilization data, including inpatient and outpatient ones, during the last 6 months before death was extracted from a registry kept in the unit. This data were combined with the corresponding local unit costs to calculate the 6, 3 and 1-month EOL cost in €2019 values. Results: A total of 122 patients met the inclusion criteria. The mean (standard deviation) age at diagnosis was 67.8 (8.9) years with 78.7% of patients being male and 55.0% diagnosed at stage IV. About 52.5% of patients had been diagnosed with adenocarcinoma, 28.7% with squamous non-small-cell lung cancer types and 18.9% with small-cell-lung cancer. The median overall survival of these patients was 10.8 months. During the EOL periods, the mean cost/patient in the last 6, 3 and 1 month were €7665, €3351 and €1009, respectively. Pharmaceutical cost was the key driver of the total cost (75% of the total 6-month) followed by radiation therapy (16.2%). The median EOL 6-month cost was marginally statistically significantly higher among patients with adenocarcinoma (€9031) compared with squamous (€6606) and to small-cell-lung cancer (€5474). Conclusion: The findings of the present study indicate that lung cancer treatment incurs high costs in Greece, mainly attributed to pharmaceutical expenses, even at the EOL phase.
Supplementary Material
File (suppl_file.docx)
- Download
- 14.81 KB
References
1.
International Agency for Research on Cancer. Global Cancer Observatory. (2018). https://gco.iarc.fr/
2.
European Respiratory Society. The economic burden of lung disease. In: Gibson GJ LR, Sibille Y, Sheffield LB (Eds). European Lung White Book. European Respiratory Society, UK, 16–27 (2013).
3.
Tsalapati K, Vardavas CI, Athanasakis K et al. Going up in ashes? Smoking-attributable morbidity, hospital admissions and expenditure in Greece. Eur. J. Public Health 24(3), 477–479 (2014).
4.
Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J. Oncol. Pract. 8(6), 75S–80S (2012).
5.
Kaye DR, Min HS, Herrel LA, Dupree JM, Ellimoottil C, Miller DC. Costs of cancer care across the disease continuum. Oncologist 23(7), 798–805 (2018).
6.
Yabroff KR, Lamont EB, Mariotto A et al. Cost of care for elderly cancer patients in the United States. J. Natl Cancer Inst. 100(9), 630–641 (2008).
7.
Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat. Clin. Pract. Oncol. 4(11), 643–656 (2007).
8.
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J. Clin. Oncol. 26(23), 3860–3866 (2008).
9.
Haque W, Verma V, Butler EB, Teh BS. Patterns of end-of-life oncologic care for stage IV non-small cell lung cancer in the United States. Anticancer Res. 39(6), 3137–3140 (2019).
10.
Kovacevic A, Dragojevic-Simic V, Rancic N et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit. Pregl. 72(4), 334–341 (2015).
11.
Langton JM, Blanch B, Drew AK, Haas M, Ingham JM, Pearson SA. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. Palliat. Med. 28(10), 1167–1196 (2014).
12.
Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J. Clin. Oncol. 30(14), 1715–1724 (2012).
13.
Wright AA, Zhang B, Ray A et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300(14), 1665–1673 (2008).
14.
Mor V, Wagner TH, Levy C et al. Association of expanded VA hospice care with aggressive care and cost for veterans with advanced lung Cancer. JAMA Oncol. 5(6), 810–816 (2019).
15.
Souliotis K, Kani C, Marioli A et al. End-of-life health-care cost of patients with lung cancer: a retrospective study. Health Serv. Res. Manag. Epidemiol. (2019) (Epub ahead of print).
16.
Greek Ministry of Health. Drug Price Bulletin, February 2019 (2019). www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/6053-epikairopoihsh-deltiwn-timwn-farmakwn-logw-dioikhtikwn-metabolwn-kai-allaghs-f-p-a-12-2-2019
17.
Greek Ministry of Health. Diagnostic Related Groups, A thens (2019). www.yyka.gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1
18.
Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyze cost data. J. Eval. Clin. Pract. 12(1), 76–86 (2006).
19.
Villaseñor JA, González-Estrada E. A variance ratio test of fit for Gamma distributions. Stat. Probabil. Lett. 96, 281–286 (2015).
20.
Bremner KE, Krahn MD, Warren JL et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat. Med. 29(10), 918–928 (2015).
21.
Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 50(2), 143–154 (2005).
22.
Oliver E, Killen J, Kiebert G et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 56(10), 785–790 (2001).
23.
Bylicki O, Rivière F, Tournier C et al. Factors associated with aggressiveness of end-of-life care for lung cancer patients and associated costs of care. Clin. Lung Cancer (2020) (Epub ahead of print).
24.
Aitini E, Adami F, Cetto GL. End of life in cancer patients: drugs or words? Ann. Oncol. 21(5), 914–915 (2010).
25.
Hung YN, Liu TW, Wen FH, Chou WC, Tang ST. Escalating health care expenditures in cancer decedents' last year of life: a decade of evidence from a retrospective population-based cohort study in Taiwan. Oncologist 22(4), 460–469 (2017).
26.
Zarogoulidou V, Panagopoulou E, Papakosta D et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. J. Thorac. Dis. 7(Suppl. 1), S12–S19 (2015).
Information & Authors
Information
Published In
Pages: 315 - 324
PubMed: 33605788
Copyright
© 2021 Future Medicine Ltd.
History
Received: 8 August 2020
Accepted: 14 December 2020
Published online: 19 February 2021
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0167
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Nikolaos Papathanasiou, Maria Spiliotopoulou, Eleni Karagkouni, Dimitrios Apostolopoulos, Paraskevi Katsakiori, John Yfantopoulos, Nikolaos Kotsopoulos, Cost-Effectiveness of Positron Emission Tomography/Computed Tomography (PET/CT) in the Initial N-Staging of Head–Neck Cancer and Comparison with CT and Magnetic Resonance Imaging (MRI), Current Oncology, 10.3390/curroncol32120677, 32, 12, (677), (2025).
- Danai Ktena, Panagiota Naoum, Evie Dalakaki, Yiannis Dimitriadis, Grace Mountain, Robert Hughes, Sherneca Clarke-Melville, Alexander Roediger, Kostas Athanasakis, Assessing the impact of anti-PD-1/PD-L1 inhibitors on cancer care health and budget in Greece, Journal of Cancer Policy, 10.1016/j.jcpo.2025.100628, 45, (100628), (2025).
- Xuanqi Pan, Katerina Togka, Hilde ten Berge, Lisa de Jong, Harry Groen, Maarten J. Postma, Eleftherios Zervas, Ioannis Gkiozos, Christoforos Foroulis, Kyriaki Tavernaraki, Sofia Lampaki, Georgia Kourlaba, Antonios Moraris, Sofia Agelaki, Konstantinos Syrigos, Lung cancer screening with volume computed tomography is cost-effective in Greece, PLOS ONE, 10.1371/journal.pone.0316351, 20, 3, (e0316351), (2025).
- George Gourzoulidis, Catherine Kastanioti, George Mavridoglou, Theodore Kotsilieris, Dikaios Voudigaris, Charalampos Tzanetakos, Does Real-World Evidence of the Economic Burden of Lung Cancer in Greece Exist? A Systematic Review of the Literature, Current Oncology, 10.3390/curroncol32030130, 32, 3, (130), (2025).
- Soraya Camargo Ito Süffert, Carlos Eduardo Aliatti Mantese, Felipe Rodrigo de Castro Meira, Katia Flavia Rosso de Oliveira Trindade, Ana Paula Beck da Silva Etges, Rafael José Vargas Alves, Claudia Giuliano Bica, End-of-Life Costs in Cancer Patients: A Systematic Review, American Journal of Hospice and Palliative Medicine®, 10.1177/10499091241285890, 42, 9, (932-961), (2024).
- George Gourzoulidis, Oresteia Zisimopoulou, Andrianos Liavas, Charalampos Tzanetakos, Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2023.2288249, 24, 3, (375-385), (2023).
- George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba, Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece, Journal of Health Economics and Outcomes Research, 10.36469/jheor.2022.32983, 9, 1, (50-57), (2022).